

d

(12) **UK Patent Application** (19) **GB** (11) **2 144 326 A**

(43) Application published 6 Mar 1985

(21) Application No 8414688

(22) Date of filing 8 Jun 1984

(30) Priority data

(31) 68965 (32) 13 Jun 1983 (33) IL

(71) Applicant
RAFA Laboratories Ltd., (Israel),
P.O. Box 405, Jerusalem 91003, Israel

(72) Inventor
Daniel Bar-Shalom

(74) Agent and/or address for service
Elkington and Fife, High Holborn House, 52/54 High
Holborn, London, WC1V 6SH

(51) INT CL⁴
A61K 31/60

(52) Domestic classification
A5B 170 26Y 402 40Y 481 483 48Y 586 58Y H
U1S 2416 A5B

(56) Documents cited
GB 1540231 EP 0085579
GB 0469526 EP 0055635
The Extra Pharmacopocia, Martindale 28th Edition
(1982) pages 234—244. Erich C. Weirich et al,
Dermatology, 152, 87—99 (1976). Psoriasis,
Proceedings of the Second International Symposium
(1976).

(58) Field of search
A5B

(54) Topical preparations containing acetyl-salicylic acid

(57) An anhydrous pharmaceutical preparation, e.g. an ointment, or lotion comprising as active ingredient at least 7% by weight, preferably 8—13%, of acetyl salicylic acid together with a suitable base is useful for the treatment of dermatological disorders, e.g. psoriasis, acne, idiopathic vitiligo, seborrheic dermatitis and bullous pemphigoid.

GB 2 144 326 A

SPECIFICATION

A Pharmaceutical Preparation Containing Acetylsalicylic Acid

The present invention relates to a
 5 pharmaceutical preparation for topical
 administration in the treatment of various
 dermatological disorders, e.g. psoriasis, acne,
 seborrheic dermatitis, idiopathic vitiligo and
 10 bullous pemphigoid, comprising as active
 ingredient acetyl salicylic acid.

Acetyl salicylic acid is a well known
 therapeutically effective compound. It is known as
 a very effective analgetic, antipyretic and anti-
 inflammatory agent. This compound has so far
 15 been administered per os, i.e. in the form of a
 tablet, capsule, etc. or in the form of an injection.

Many experiments have been made to
 administer acetyl salicylic acid not in the form of
 tablets but in a more pleasant form. Thus, Israeli
 20 Patent Specification No. 44774 claims a
 pharmaceutical composition which is to be
 administered per os after it has been dissolved in
 water. The aqueous solution has to be
 administered quickly as otherwise the acetyl
 25 salicylic acid will be hydrolysed. Moreover, such
 an aqueous solution certainly cannot be stored
 for an extended period of time.

From Israeli Patent Specification No. 44485
 there is known a stable liquid acetyl salicylic acid
 30 composition which is also administered per os.
 The advantage of this solution is that it yields a
 more palatable form of administration which is
 important in pediatric practice. The application of
 this composition externally has not been
 35 considered.

From Psoriasis, Proceedings of the Second
 International Symposium, 1976, there are known
 experiments in which compositions were
 prepared enabling the external use of acetyl
 40 salicylic acid in the treatment of certain diseases.
 The concentration of the acetyl salicylic acid in
 said composition was 1—2%. (All percentages
 are given herein in percentages by weight).
 However, the authors specifically stated that said
 45 compositions were not effective against psoriasis.

The inhibitory effect of certain compounds,
 inter alia, acetyl salicylic acid on the development
 of erythema in guinea pigs was tested by Erich C.
 Weirich et al, Dermatology, 152, 87—99 (1976).
 50 The concentration of said compounds, e.g. of
 acetyl salicylic acid in the tested composition was
 0.05—5%. A certain external anti-inflammatory
 effect was observed for acetyl salicylic acid.
 However, this effect was not sufficient and in
 55 particular it did not give any hint that acetyl
 salicylic acid in a concentration of at least 7% is
 very effective in the treatment of dermatological
 disorders, in particular those indicated above.

The present invention thus consists in an
 60 anhydrous pharmaceutical preparation for topical
 administration in the treatment of dermatological
 disorders comprising as active ingredient at least
 7% of acetyl salicylic acid together with a suitable
 base.

65 Said preparation may have any suitable form,
 e.g. an ointment, solution, emulsion, lotion, etc.

The basis of said preparation in connection
 with the present invention should be anhydrous,
 physiologically acceptable and compatible with
 70 the acetyl salicylic acid. Suitable bases are for
 example, liquid paraffin, lanolin, white soft
 paraffin, white bees wax, hard paraffin and certain
 alcohols, e.g. ethanol, propanol, isopropyl alcohol,
 glycerol and glycol and mixtures thereof. Said
 75 bases are chosen in accordance with the specific
 requirements of the preparation.

The concentration of the acetyl salicylic acid
 within the preparation varies to a certain degree.
 However, it has been found that the preferred
 80 concentration is 8—13%.

The present invention consists also in a
 method for the treatment of dermatological
 disorders comprising administering a preparation
 as defined above in pre-determined intervals and
 85 pre-determined doses. The doses administered
 are preferably 7—15 mg/mm of skin and the
 intervals between each dose is about 24 hours
 until the lesion disappears.

The method in accordance with the present
 90 invention is in particular suitable in the treatment
 of psoriasis, acne, idiopathic vitiligo, seborrheic
 dermatitis and bullous pemphigoid.

The present invention will now be illustrated
 with reference to the accompanying examples
 95 without being restricted by them. In all said
 examples the preparations were prepared by
 suitable pharmaceutical methods, i.e. by way of
 admixing the separate ingredients until
 homogenous preparation was obtained.

100 EXAMPLE 1

An ointment comprising the following
 ingredients was prepared:

Acetyl salicylic acid	12.5 g
White bees wax	1.75 g
105 Hard paraffin	7.0 g
White soft paraffin up to	100.0 g
<i>white petrolatum</i>	

Seven individuals suffering from psoriatic
 skin were treated with the above ointment. The
 ointment was smeared on discrete marked areas
 110 twice daily for at least two weeks. In six of the
 cases complete healing was achieved within 7—
 11 days, while there was a slight improvement on
 the remaining one.

EXAMPLE 2

115 An ointment comprising the following
 ingredients was prepared:

Acetyl salicylic acid	10.0 g
Lanolin 10% in soft white paraffin up to	100.0 g

The preparation was applied to the psoriatic skin of 15 individuals using different criteria for control (for example: a limited area within a lesion was smeared and compared with the rest, one limb was smeared and compared with the second untreated one, etc.) In 13 cases there was a noticeable improvement, in one very slight and in one no change.

While the average time for complete clearing of the lesion was 8 days, there was a remarkable case of a young girl whose ears were cleared completely within 48 hours.

EXAMPLE 3

A lotion comprising the following ingredients was prepared:

Acetyl salicylic acid	10 g
Propylene Glycol up to	100 g

The lotion was rubbed each day on the scalp of 8 psoriatic individuals. In all cases there was a great improvement; in 6 of them after 2 weeks of treatment the scales disappeared completely.

EXAMPLE 4

An ointment comprising the following ingredients was prepared:

Acetyl salicylic acid	10 g
Lanoline	9 g
Soft white paraffin	81 g

50 patients suffering from psoriatic lesions were treated with said ointment. These patients had plaques of medium size which were distributed on the arms, legs or body (particularly the region of the neck). All the lesions were treated with the ointment for about 2 weeks. Complete healing was observed in 50% of the cases, while those patients with very large lesions reported a great improvement but not complete healing. It was noted that lesions in the area of the head and neck cleared more rapidly than lesions on the arms, whilst lesions on the legs cleared more slowly. Of the 50 treated cases 2 did not respond to treatment. In one case the patient discontinued the therapy after 2 treatments. No explanation was given.

3 of the treated patients were suffering from diabetes who were unable to use corticosteroids. These 3 patients reported marked improvement following application of the ointment for about 2 weeks. The rate of improvement was however slower, as compared with non-diabetic patients.

EXAMPLE 5

A lotion comprising the following ingredients was prepared:

Acetyl salicylic acid	10 g
Ethanol	90 g

80 patients suffering from acne were treated with said lotion. Following several days of treatment no new lesions or pustules appeared and the acne rapidly cleared. All were instructed to discontinue other forms of acne treatment and to use only the lotion once a day and clearing was observed within 2 days. One female patient aged 28 who had complained of severe outbreaks of acne coinciding with the menses, reported that treatment with the lotion cleared her acne completely within a few days.

EXAMPLE 6

4 cases of previously diagnosed idiopathic vitiligo were treated with the ointment described in Example 4. Complete healing, i.e. repigmentation of the area of the skin was observed in all four cases following treatment extending over a period of 6 to 12 weeks.

EXAMPLE 7

A lotion comprising the following ingredients was prepared:

Acetyl salicylic acid	8 g
Propylene glycol/Isopropyl Alcohol 50:50	92 g

This lotion was tried on patients, in particular young children aged 3 to 5 years suffering from seborrheic dermatitis and was found to be effective.

EXAMPLE 8

A female aged 80 years with an eruption which had been diagnosed as bullous pemphigoid was treated with the ointment described in Example 4 for 3 weeks. The bullae disappeared completely and no recurrence was reported.

EXAMPLE 9

An albino who was unable to tolerate exposure to sunlight was treated with the ointment described in Example 4 which was applied to the face. The application prevented the erythema caused by the exposure to radiant heat.

CLAIMS

1. An anhydrous pharmaceutical preparation for topical administration in the treatment of dermatological disorders comprising as active ingredient at least 7% of acetylic acid together with a suitable base.

2. A preparation according to Claim 1, wherein the concentration of acetyl salicylic acid is 8—13%.

3. A preparation according to Claim 1 or 2 being an ointment.

4. A preparation according to Claim 1 or 2 being a lotion.

5. A preparation according to any of Claims 1 to 4, wherein the base is selected among the group comprising liquid paraffin, lanolin, white soft paraffin, white bees wax, hard paraffin and

certain alcohols, e.g. ethanol, propanol, isopropyl alcohol, glycerol and glycol and mixtures thereof.

6. An anhydrous pharmaceutical preparation for topical administration in the treatment of

5 dermatological disorders substantially as hereinbefore described with reference to the Examples.

Printed in the United Kingdom for Her Majesty's Stationery Office, Demand No. 8818935, 3/1985. Contractor's Code No. 6378.
Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.